JUUL's New Flavors: altpods Compatible Pods Launch in Japan

Business by 2FIRSTS.ai
May.20.2024
JUUL's New Flavors: altpods Compatible Pods Launch in Japan
Beyond Vape Japan launches five new flavors of JUUL-compatible e-cigarette pods "altpods" in Tokyo, available for purchase online.

According to a report from Shin-Shouhin on May 20th, the e-cigarette brand "JUUL" has introduced five new flavors for its compatible pods, named "altpods".

 

Recently, Beyond Vape Japan, operated by the Tokyo-based AMDIA company, has launched electronic pods called "altpods" that are compatible with JUUL e-cigarettes. Each package contains 4 pods, with each pod capable of approximately 200 puffs. The retail price, including tax, is 1,880 Japanese yen (12.07 US dollars).

 

The new product can be purchased on the official website, Rakuten Market, Amazon, Yahoo Shopping, and Q10. In addition, the promotion for "altpods" will continue until May 31st.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Thai Vape User Numbers Rose More Than 11-Fold in Three Years, Group Says Ban Should Be Reassessed
Thai Vape User Numbers Rose More Than 11-Fold in Three Years, Group Says Ban Should Be Reassessed
A network of e-cigarette users in Thailand has urged the new government to review the country’s vape ban, saying official data show that use has risen sharply despite more than a decade of prohibition.
Mar.27 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Costa Rica’s Constitutional Court Rejects Challenge, New Vape Rules to Take Effect on August 6
Costa Rica’s Constitutional Court Rejects Challenge, New Vape Rules to Take Effect on August 6
Costa Rica’s Constitutional Court has rejected an injunction seeking to stop a new vape regulation from taking effect, ruling that there was no specific harm to constitutional rights. As a result, Technical Regulation RTCR 519-2025, promoted by the Health Ministry, will enter into force on August 6 as originally planned.
Mar.20 by 2FIRSTS.ai
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Concerns about the effects of vaping on young people and public health were raised at County Hall, the report said, with Cllr Chris Jarman saying it may one day be viewed as “akin to asbestos.” Jarman cited NHS-related research and a case highlighted by Hull University Teaching Hospitals NHS Trust: a 15-year-old admitted with chest pain and breathing difficulty who reported cannabis use and vaping about 500 puffs per day and was diagnosed via CT with “air leak syndrome.”
Feb.27 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11